ACUR:OTC-Acura Pharmaceuticals, Inc (USD)

COMMON STOCK | Drug Manufacturers—Specialty & Generic | OTC

Last Closing Price

USD 0.32

Change

0.00 (0.00)%

Market Cap

USD 6.50M

Volume

3.65K

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Acura Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. The company has six additional opioid products in various stages of formulation development. Acura Pharmaceuticals, Inc. has collaboration and license agreements with Egalet US, Inc.; and Egalet Ltd. to manufacture and commercialize Oxaydo products worldwide; and development and commercialization agreement with Abuse Deterrent Pharma, LLC to develop LTX-03, an immediate-release tablets utilizing LIMITx technology. The company was founded in 1935 and is based in Palatine, Illinois.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-07-03 )

Largest Industry Peers for Drug Manufacturers—Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
TKPHF Takeda Pharmaceutical Company ..

N/A

USD58.40B 140.96 0.15
MKKGY MERCK Kommanditgesellschaft au..

N/A

USD50.86B 28.85 14.42
MKGAF MERCK Kommanditgesellschaft au..

N/A

USD49.13B 29.26 14.42
ESALF Eisai Co., Ltd

N/A

USD25.20B 18.36 0.13
ESALY Eisai Co., Ltd

N/A

USD23.34B 20.44 0.13
SGIOY Shionogi & Co., Ltd

N/A

USD19.91B 16.61 0.10
SGIOF Shionogi & Co., Ltd

N/A

USD19.35B 16.69 0.10
TEVJF Teva Pharmaceutical Industries..

N/A

USD14.22B 483.60 28.33
SFOSF Shanghai Fosun Pharmaceutical ..

N/A

USD12.06B 19.46 2.45
MTZPY Mitsubishi Tanabe Pharma Corpo..

N/A

USD10.43B 79.00 0.21

ETFs Containing ACUR

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers—Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 40.00% 78% C+ 80% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 40.00% 77% C+ 79% C+
Trailing 12 Months  
Capital Gain 19.26% 84% B 76% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 19.26% 83% B 74% C
Trailing 5 Years  
Capital Gain -92.60% 26% F 12% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -92.60% 26% F 12% F
Average Annual (5 Year Horizon)  
Capital Gain -24.41% 5% F 4% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -24.41% 5% F 4% F
Risk Return Profile  
Volatility (Standard Deviation) 59.86% 53% F 43% F
Risk Adjusted Return -40.77% 14% F 11% F
Market Capitalization 6.50M 49% F 38% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers—Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio N/A N/A N/A N/A N/A
Price / Cash Flow Ratio -10.51 83% B 86% B
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital -77.71% 23% F 9% F
Return on Assets -19.23% 48% F 29% F
Debt to Equity Ratio -126.56% 92% A- 96% A
Technical Ratios  
Short Ratio 0.73 50% F 56% F
Short Percent 1.20% 38% F 49% F
Beta 1.22 45% F 36% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.